Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06593600 | Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) | PHASE2 | ACTIVE NOT_RECRUITING | 82 | — | — | Nov 13, 2024 | Jul 6, 2026 | May 4, 2026 | 16 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| Low Dose | EXPERIMENTAL | Randomized 1:1:1 |
| High Dose | EXPERIMENTAL | Randomized 1:1:1 |
| Matching Placebo | PLACEBO_COMPARATOR | Randomized 1:1:1 |
| Name | Type | Description |
|---|---|---|
| REGN7544 | DRUG | Subcutaneous (SC) administration |
| Placebo | DRUG | SC administration |
Key Inclusion Criteria: 1. Is diagnosed with POTS and demonstrates consensus criteria (a), (b), (c) and (d) below during screening: 1. Increase in HR ≥30 beats per minute (BPM) within 10 minutes of changing from supine to a standing position, as described in the protocol 2. Absence of orthos...